-
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
July 22, 2026 02:00 ET | Source: Healx Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310, an investigational oral combination…
-
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
July 13, 2026 20:35 ET | Source: Mesoblast Limited NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L…
-
No easy answers: European research consortia take on major challenges
COPENHAGEN, Denmark, July 10, 2026 (GLOBE NEWSWIRE) — Nine new Challenge Programme grants from the Novo Nordisk Foundation will support ambitious research across fungal diseases, cardiometabolic disease, soil health and non-equilibrium biological systems. With a European expansion, the 2026 awards unite strong research groups and diverse expertise across Europe in the pursuit of novel knowledge…
-
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the…
-
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
June 30, 2026 20:38 ET | Source: Mesoblast Limited NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration (FDA) and has requested a…
-
Dyne Therapeutics Appoints Barry Greene to Board of Directors
June 22, 2026 16:10 ET | Source: Dyne Therapeutics, Inc. WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Barry Greene to its Board of Directors. Mr. Greene brings more…
-
Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health
Milestone financing and R&D collaboration advances gene therapy programs targeting chronic and age-related diseases in companion animals. NORWALK, Conn., June 11, 2026 /PRNewswire/ — Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congratulates its portfolio company Rejuvenate Bio on the successful close of a $6 million financing round and…
-
Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH)
European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels June 05, 2026 02:00 ET | Source: Chiesi Global Rare Diseases PARMA, Italy, June 05, 2026 (GLOBE NEWSWIRE) — Chiesi Global Rare Diseases, a…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.